CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, haemophilia, von Willebrand disease and other bleeding disorders and the prevention of haemolytic diseases in the newborn. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring's products are produced at facilities in Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois, in accordance with international safety and quality standards.
CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.co.uk.